Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk lost $70 billion in market value after lowering its 2025 sales outlook and appointing Maziar Mike Doustdar as ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk will hold its Q2 FY2025 earnings call on Wednesday, before the market opens. The company s having a terrible ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool ...